Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart failure than someone without diabetes. Heart failure is a condition in which the heart fails to efficiently pump oxygenated blood through the body, while diabetes is a condition that causes blood sugar levels to rise. Today we’ll be discussing this issue with reference to Eli Lilly & Co. (NYSE: LLY), Novo Nordisk (NYSE: NVO), Sanofi (NASDAQ: SNY) and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL).
The globally accepted treatment for diabetes is insulin, and big pharma companies Eli Lilly & Co., Novo Nordisk, and Sanofi all manufacture insulin to combat this debilitating disease. Meanwhile, heart failure comes in various forms, and some, such as acute myocarditis and diastolic heart failure, currently have no recognized standard of care.
With the conditions being so closely entwined, it makes sense that tackling one could reduce the risk of developing the other. While lifestyle changes can reduce the likelihood of heart failure, this is not as easy as it sounds. Every year, over 550k new cases are diagnosed in the U.S. That’s why Cardiol Therapeutics is working vigorously to develop therapeutic treatments to help people live more comfortably with this destructive disease.
Currently, the company has one multi-national clinical trial ongoing and another expected to commence shortly. Strong pre-clinical evidence shows the molecule being investigated could be a complete gamechanger, creating several reasons to invest in this exciting company.
COMBATING HEART FAILURE
Cardiol Therapeutics is a clinical-stage life sciences company focused on researching and developing an anti-fibrotic and anti-inflammatory therapy to treat cardiovascular disease (CVD). Its lead product candidate, CardiolRx, is a pharmaceutically produced oral formulation being clinically developed for cardiovascular medicine use.
Based on an extensive review of the scientific literature on the subject, David Elsley, Cardiol’s President and CEO, along with his co-founders, discovered a molecule of strong interest in treating heart failure due to its anti-fibrotic, anti-inflammatory, and cardioprotective properties.
TREATING DIASTOLIC HEART FAILURE
Diastolic heart failure represents around half of all heart failure. Furthermore, heart failure is possibly the most significant medical issue the western world faces. And this is rapidly escalating due to the rise of diabetes, obesity, and high blood pressure.
That’s why Cardiol Therapeutics has made treating diastolic heart failure its overarching goal, with its ongoing pre-clinical development of a solution its priority.
Cardiol’s administration of CardiolRx for acute myocarditis patients is in an oral formulation. For treating diastolic heart failure patients, the CardiolRx formulation is expected to be administered via subcutaneous injection, similar to the way people with diabetes use insulin.
The oral formulation of CardiolRx allows the treatment to be administered quickly and aggressively at very high doses. This is particularly important when dealing with acute myocarditis patients who require urgent care.
However, diastolic heart failure tends to be much more chronic than urgent and, in many cases, is something patients must learn to live with. That’s why a subcutaneous formulation is a more suitable form of treatment that could lead to less frequent dosing. Cardiol believes its subcutaneous formulation will allow it to be injected and taken up via the bloodstream.
Indeed, the company has some very compelling pre-clinical data that it presented at the American College of Cardiology’s (ACC) 69th virtual Annual Scientific Session & Expo together with the World Congress of Cardiology in 2020.
If Cardiol Therapeutics achieves its long-term goal of developing a treatment for diastolic heart failure, the addressable market is huge.
Indeed, this is a colossal health problem in the western world with no current standard of care. Plus, it is a condition that continues to grow in the developed world due to rising cases of diabetes, hypertension, and obesity.
The Cardiol Therapeutics team aspires to become a much bigger organization by developing life-changing drugs for this growing area of concern.
In achieving its ultimate objectives, Cardiol Therapeutics could give hope of better managing diastolic heart failure to all those suffering. Treating this serious health condition with a formulation that has an active pharmaceutical ingredient that’s structurally bioidentical to its organic counterpart and free from impurities could offer tremendous relief to many.
One of the reasons heart failure poses a mounting burden to the healthcare system is growing diabetes cases.
Eli Lilly & Co. (NYSE: LLY) uses biotechnology, chemistry, and genetic medicine, to advance new discoveries in redefining diabetes care and treating obesity. Its SURMOUNT-3 and 4 study varies from 72 to 88 weeks. SURMOUNT -1 will continue through 176 weeks to evaluate whether tirzepatide can slow the time to onset of type 2 diabetes in participants who had prediabetes at the time of entering the clinical trial.
Novo Nordisk (NYSE: NVO) aims to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. The company is paving the way for a Phase 3 program to discover the prospect of CagriSema in obesity and diabetes.
Sanofi’s (NASDAQ: SNY) recent type 1 diabetes study into second-generation insulins provides clinicians with valuable information. It shows how second-generation basal insulins compare to clinically relevant outcomes such as Time in Range, glucose variability, and hypoglycaemia.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult =a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated twenty six hundred dollars for news coverage of the current press releases issued by Cardiol Therapeutics by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757